

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Umstead John W. V</u> (Last) (First) (Middle) 700 PARK OFFICES DRIVE, SUITE 200 (Street) RESEARCH TRIANGLE NC 27709 PARK (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>G1 Therapeutics, Inc. [GTHX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2024		A		37,300 ⁽¹⁾	A	\$0.00 ⁽²⁾	131,186 ⁽³⁾	D	
Common Stock	01/03/2024		S		253 ⁽⁴⁾	D	\$3.1189 ⁽⁵⁾	130,933 ⁽⁶⁾	D	
Common Stock	01/03/2024		S		379 ⁽⁴⁾	D	\$3.1189 ⁽⁵⁾	130,554 ⁽⁷⁾	D	
Common Stock	01/04/2024		S		111 ⁽⁴⁾	D	\$2.9423 ⁽⁸⁾	130,443 ⁽⁹⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Options (Right to Buy)	\$2.97	01/03/2024		A		74,500		(10)	01/03/2034	Common Stock	74,500		D	

Explanation of Responses:

- Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- Each RSU represents a contingent right to receive one share of Issuer common stock.
- Represents (i) 2,749 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,500 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
- The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- The price represents the weighted average price with a low of \$3.08 and a high of \$3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents (i) 2,996 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
- Represents (i) 3,367 shares of common stock; (ii) 637 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
- The price represents the weighted average price with a low of \$2.89 and a high of \$3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents (i) 3,468 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 50,000 RSUs from award granted on March 15, 2023; (vi) 35,000 RSUs from award granted on May 10, 2023; and (vii) 37,300 RSUs from award granted on January 3, 2024.
- The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

/s/ Monica Roberts Thomas, 01/05/2024
attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that the undersigned hereby constitutes and appoints each of Monica Roberts Thomas, General Counsel, of G1 Therapeutics, Inc. (the "Company"), Sandi James, Director, Legal, of the Company, and Jason McCaffrey, Raven Sun, Justin Omalev, Charles Smith, Tanya Sylla, and Brenda Meyette of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed on December 6, 2023.

/s/ John W. Umstead V
Signature

John W. Umstead V
Print Name